Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.
In this indirect treatment comparison for obesity treatment in adults without T2D, with obesity, or overweight with ≥1 ORC, compared with semaglutide, tirzepatide 10 or 15’mg was associated with improvements in weight reduction, body composition and several cardiometabolic risk factors and generally similar safety prof...